Desperate patients get early access to promising new drug

NCT ID NCT07629401

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This program allows individual patients with serious or life-threatening conditions to request early access to retatrutide before it is fully approved. The drug is intended to help control the disease, but ongoing management may still be needed. Eligibility is determined on a case-by-case basis by the sponsor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.